Intellia Therapeutics Inc's Comment on Supply Chain
The company faces risks related to raw materials, including potential contamination and regulatory restrictions that may necessitate operational changes. There is significant uncertainty regarding coverage and reimbursement for biological products, such as gene and cellular therapies, in the United States and other countries. Coverage decisions are made by third-party payors, including government authorities, managed care providers, health maintenance organizations, and private insurers. Obtaining approval for coverage and reimbursement is a complex process that requires scientific and clinical data on a payor-by-payor basis, with no assurance of success. Even when coverage is granted, reimbursement rates may be insufficient to achieve profitability, particularly due to the higher costs of goods and the need for long-term follow-up evaluations associated with gene editing products. Additionally, mandatory discounts, rebates, and initiatives to reduce healthcare costs may further restrict coverage and reimbursement levels.
Intellia Therapeutics Inc's Comment on Supply Chain
The company faces risks related to raw materials, including potential contamination and regulatory restrictions that may necessitate operational changes. There is significant uncertainty regarding coverage and reimbursement for biological products, such as gene and cellular therapies, in the United States and other countries. Coverage decisions are made by third-party payors, including government authorities, managed care providers, health maintenance organizations, and private insurers. Obtaining approval for coverage and reimbursement is a complex process that requires scientific and clinical data on a payor-by-payor basis, with no assurance of success. Even when coverage is granted, reimbursement rates may be insufficient to achieve profitability, particularly due to the higher costs of goods and the need for long-term follow-up evaluations associated with gene editing products. Additionally, mandatory discounts, rebates, and initiatives to reduce healthcare costs may further restrict coverage and reimbursement levels.
Sources:
Intellia Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Intellia Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
